Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Radiopharm Theranostics - Share Facility Agreement of up to A$12.5m addendum (ASX:RAD)

Further to Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or Company) announcement earlier today, the issue of shares under the Share Subscription Agreement is amended as below and attached. ...read more

Radiopharm Theranostics secures Share Facility Agreement of up to A$12.5m (ASX:RAD)

-- Up to A$12.5 million investment by US institutional investor, Lind Partners. -- Under a Share Subscription Agreement, RAD will receive A$1.2 million, with up to a further A$11.3 million in fundi...read more

Radiopharm Theranostics - RAD 502 can halt tumour progression and prolong survival (ASX:RAD)

Study by David Ulmert and colleagues demonstrated that non-invasive clinical imaging and targeted radioimmunotherapy with DUNP19 (RAD 502) can halt tumor progression and prolong survival in var...read more

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:RAD)

-- Phase 1 clinical trial initiated (RAD204) for PDL1-positive non-small cell lung cancer and second site announced -- Phase 1 clinical trial initiated in New York to assess 68Ga-Trivehexin's (...read more

Radiopharm Theranostics - Investor Presentation (ASX:RAD)

To view the presentation, download the attached PDF.

Radiopharm Theranostics - Placement of Entitlement Offer Shortfall (ASX:RAD)

On 31 October 2023, Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or Company) announced the details of a non-renounceable entitlement offer (Entitlement Offer) to raise approximate...read more

Radiopharm Theranostics - 2nd Australian site for Nanomab-PDL-1 Phase 1 trial (ASX:RAD)

-- Ethics Committee approval received from Hollywood Private Hospital in Perth, WA -- Patient recruitment to commence shortly -- Phase 1 study in 21 patients designed to evaluate the safety and ef...read more

Radiopharm Theranostics - Phase 1 Therapeutic NSCLC (Lung Cancer) Trial Opens 4 Jan (ASX:RAD)

-- Successful Site Initiation at Princess Alexandra Hospital, Brisbane for RAD 204 (PDL-1 nanobody) therapeutic Phase 1 trial -- Phase 1 First-In-Human study in 21 patients designed to evaluate saf...read more

Radiopharm Theranostics - Completion of Entitlement Offer (ASX:RAD)

Radiopharm receives $4.85M R&D tax incentive (ASX:RAD)

Sydney, Australia – 21 November 2023 – Radiopharm Theranostics Limited (ASX:RAD), a developer of a world class platform of radiopharmaceutical products for both diagnostic and thera...read more

Radiopharm Theranostics - Entitlement Offer Documents (ASX:RAD)

Sydney, Australia – 8 November 2023 – Radiopharm Theranostics (ASX:RAD), a developer of a worldclass platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is...read more

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:RAD)

Highlights: FDA IND for Trivehexin (RAD 301) diagnostic Phase 1 pancreatic clinical trial RAD 301 additional data on 33 patients presented at 2023 European Association of Nuclear ...read more

Radiopharm Theranostics - Entitlement Offer to raise approximately $10 million (ASX:RAD)

Key Points -- Non-renounceable entitlement offer to raise up to approximately $10 million (before direct offer costs). -- Offer price of $0.07 per new share, a 30.0% discount to the closing pric...read more

RAD receives approval for Phase 1 therapeutic study of NSCLC (ASX:RAD)

Sydney, Australia – 9 October 2023 – Radiopharm Theranostics (ASX:RAD), a developer of a worldclass platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is ...read more

Dividend/Distribution - RFF (ASX:RFF)

To view the Notification of dividend / distribution, download the attached PDF.

Viewing: 16 - 30 of 200 Previous | Next